Mechanisms of sphingosine 1-phosphate receptor signalling in cancer

Cellular Signalling

Volumn 34, Issue , 2017, Pages 66-75

  Patmanathan, Sathya Narayanan ^a   Wang, Wei ^b   Yap, Lee Fah ^a   Herr, Deron R ^b   Paterson, Ian C ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer; GPCR; Sphingosine 1 phosphate

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; AMISELIMOD; ANTINEOPLASTIC AGENT; CANNABINOID RECEPTOR; CERALIFIMOD; CERAMIDASE; CS 0777; EPINEPHRINE; G PROTEIN COUPLED RECEPTOR; GSK 2018682; GUANOSINE TRIPHOSPHATASE; LEUKOTRIENE RECEPTOR; LYSOPHOSPHOLIPID RECEPTOR; OZANIMOD; PONESIMOD; PROSTANOID RECEPTOR; RHO FACTOR; RHODOPSIN; SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; LYSOPHOSPHOLIPID; PROTEIN TYROSINE KINASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; HUMAN; MALIGNANT NEOPLASM; MULTIPLE SCLEROSIS; NEOVASCULARIZATION (PATHOLOGY); PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REVIEW; SEQUENCE HOMOLOGY; TUMOR CELL; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 85015389787     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2017.03.002     Document Type: Review

References (134)

1. [1] Taha, T.A., Hannun, Y.A., Obeid, L.M., Sphingosine kinase: biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol. 39:2 (2006), 113–131.
2. [2] Hisano, Y., Kobayashi, N., Yamaguchi, A., Nishi, T., Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS One, 7(6), 2012, e38941.
3. [3] Osborne, N., Brand-Arzamendi, K., Ober, E.A., Jin, S.W., Verkade, H., Holtzman, N.G., Yelon, D., Stainier, D.Y., The spinster homolog, two of hearts, is required for sphingosine 1-phosphate signaling in zebrafish. Curr. Biol. 18:23 (2008), 1882–1888.
4. [4] Hait, N.C., Allegood, J., Maceyka, M., Strub, G.M., Harikumar, K.B., Singh, S.K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S., Spiegel, S., Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science (New York, N.Y.) 325:5945 (2009), 1254–1257.
5. [5] Spiegel, S., Milstien, S., Functions of the multifaceted family of sphingosine kinases and some close relatives. J. Biol. Chem. 282:4 (2007), 2125–2129.
6. [6] Strub, G.M., Paillard, M., Liang, J., Gomez, L., Allegood, J.C., Hait, N.C., Maceyka, M., Price, M.M., Chen, Q., Simpson, D.C., Kordula, T., Milstien, S., Lesnefsky, E.J., Spiegel, S., Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J. 25:2 (2011), 600–612.
7. [7] Alvarez, S.E., Milstien, S., Spiegel, S., Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol. Metab. 18:8 (2007), 300–307.
8. [8] Takabe, K., Paugh, S.W., Milstien, S., Spiegel, S., “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol. Rev. 60:2 (2008), 181–195.
9. [9] Brinkmann, V., Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115:1 (2007), 84–105.
10. [10] Jo, E., Sanna, M.G., Gonzalez-Cabrera, P.J., Thangada, S., Tigyi, G., Osborne, D.A., Hla, T., Parrill, A.L., Rosen, H., S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 12:6 (2005), 703–715.
11. [11] Takashima, S., Sugimoto, N., Takuwa, N., Okamoto, Y., Yoshioka, K., Takamura, M., Takata, S., Kaneko, S., Takuwa, Y., G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase. Cardiovasc. Res. 79:4 (2008), 689–697.
12. [12] Takuwa, Y., Okamoto, Y., Yoshioka, K., Takuwa, N., Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim. Biophys. Acta 1781:9 (2008), 483–488.
13. [13] Jiang, L.I., Collins, J., Davis, R., Lin, K.M., DeCamp, D., Roach, T., Hsueh, R., Rebres, R.A., Ross, E.M., Taussig, R., Fraser, I., Sternweis, P.C., Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J. Biol. Chem. 282:14 (2007), 10576–10584.
14. [14] Kim, Y.M., Lim, S.C., Han, C.Y., Kay, H.Y., Cho, I.J., Ki, S.H., Lee, M.Y., Kwon, H.M., Lee, C.H., Kim, S.G., G(alpha)12/13 induction of CYR61 in association with arteriosclerotic intimal hyperplasia: effect of sphingosine-1-phosphate. Arterioscler. Thromb. Vasc. Biol. 31:4 (2011), 861–869.
15. [15] Bjorklund, S., Palmberg, S., Rask, S., Westerdahl, A.C., Tornquist, K., Effects of sphingosine 1-phosphate on calcium signaling, proliferation and S1P2 receptor expression in PC Cl3 rat thyroid cells. Mol. Cell. Endocrinol. 231:1–2 (2005), 65–74.
16. [16] Im, D.S., Tomura, H., Tobo, M., Sato, K., Okajima, F., Enhancement of sphingosine 1-phosphate-induced phospholipase C activation during G(0)-G(1) transition in rat hepatocytes. J. Pharmacol. Sci. 95:2 (2004), 284–290.
17. [17] Lee, M.J., Thangada, S., Paik, J.H., Sapkota, G.P., Ancellin, N., Chae, S.S., Wu, M., Morales-Ruiz, M., Sessa, W.C., Alessi, D.R., Hla, T., Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol. Cell 8:3 (2001), 693–704.
18. [18] Pyne, N.J., Pyne, S., Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 10:7 (2010), 489–503.
19. [19] Pyne, S., Adams, D.R., Pyne, N.J., Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances. Prog. Lipid Res. 62 (2016), 93–106.
20. [20] Heffernan-Stroud, L.A., Obeid, L.M., Sphingosine kinase 1 in cancer. Adv. Cancer Res. 117 (2013), 201–235.
21. [21] Kendall, A.C., Nicolaou, A., Bioactive lipid mediators in skin inflammation and immunity. Prog. Lipid Res. 52:1 (2013), 141–164.
22. [22] Kihara, Y., Maceyka, M., Spiegel, S., Chun, J., Lysophospholipid receptor nomenclature review: IUPHAR review 8. Br. J. Pharmacol. 171:15 (2014), 3575–3594.
23. [23] An, S., Bleu, T., Huang, W., Hallmark, O.G., Coughlin, S.R., Goetzl, E.J., Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett. 417:3 (1997), 279–282.
24. [24] Im, D.S., Heise, C.E., Ancellin, N., O'Dowd, B.F., Shei, G.J., Heavens, R.P., Rigby, M.R., Hla, T., Mandala, S., McAllister, G., George, S.R., Lynch, K.R., Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J. Biol. Chem. 275:19 (2000), 14281–14286.
25. [25] Lee, M.J., Van Brocklyn, J.R., Thangada, S., Liu, C.H., Hand, A.R., Menzeleev, R., Spiegel, S., Hla, T., Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science (New York, N.Y.) 279:5356 (1998), 1552–1555.
26. [26] Yamazaki, Y., Kon, J., Sato, K., Tomura, H., Sato, M., Yoneya, T., Okazaki, H., Okajima, F., Ohta, H., Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2 +) signaling pathway. Biochem. Biophys. Res. Commun. 268:2 (2000), 583–589.
27. [27] Hecht, J.H., Weiner, J.A., Post, S.R., Chun, J., Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135:4 (1996), 1071–1083.
28. [28] An, S., Bleu, T., Hallmark, O.G., Goetzl, E.J., Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273:14 (1998), 7906–7910.
29. [29] Im, D.S., Heise, C.E., Harding, M.A., George, S.R., O'Dowd, B.F., Theodorescu, D., Lynch, K.R., Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57:4 (2000), 753–759.
30. [30] Parrill, A.L., Wang, D., Bautista, D.L., Van Brocklyn, J.R., Lorincz, Z., Fischer, D.J., Baker, D.L., Liliom, K., Spiegel, S., Tigyi, G., Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J. Biol. Chem. 275:50 (2000), 39379–39384.
31. [31] Hanson, M.A., Roth, C.B., Jo, E., Griffith, M.T., Scott, F.L., Reinhart, G., Desale, H., Clemons, B., Cahalan, S.M., Schuerer, S.C., Sanna, M.G., Han, G.W., Kuhn, P., Rosen, H., Stevens, R.C., Crystal structure of a lipid G protein-coupled receptor. Science (New York, N.Y.) 335:6070 (2012), 851–855.
32. [32] Schurer, S.C., Brown, S.J., Gonzalez-Cabrera, P.J., Schaeffer, M.T., Chapman, J., Jo, E., Chase, P., Spicer, T., Hodder, P., Rosen, H., Ligand-binding pocket shape differences between sphingosine 1-phosphate (S1P) receptors S1P1 and S1P3 determine efficiency of chemical probe identification by ultrahigh-throughput screening. ACS Chem. Biol. 3:8 (2008), 486–498.
33. [33] Chew, W.S., Wang, W., Herr, D.R., To fingolimod and beyond: the rich pipeline of drug candidates that target S1P signaling. Pharmacol. Res. 113:Pt A (2016), 521–532.
34. [34] Kunkel, G.T., Maceyka, M., Milstien, S., Spiegel, S., Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat. Rev. Drug Discov. 12:9 (2013), 688–702.
35. [35] Cohen, J.A., Chun, J., Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 69:5 (2011), 759–777.
36. [36] Paugh, S.W., Payne, S.G., Barbour, S.E., Milstien, S., Spiegel, S., The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554:1–2 (2003), 189–193.
37. [37] Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C.L., Rupprecht, K., Parsons, W., Rosen, H., Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (New York, N.Y.) 296:5566 (2002), 346–349.
38. [38] Oo, M.L., Thangada, S., Wu, M.T., Liu, C.H., Macdonald, T.L., Lynch, K.R., Lin, C.Y., Hla, T., Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem. 282:12 (2007), 9082–9089.
39. [39] Matloubian, M., Lo, C.G., Cinamon, G., Lesneski, M.J., Xu, Y., Brinkmann, V., Allende, M.L., Proia, R.L., Cyster, J.G., Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:6972 (2004), 355–360.
40. [40] Choi, J.W., Gardell, S.E., Herr, D.R., Rivera, R., Lee, C.W., Noguchi, K., Teo, S.T., Yung, Y.C., Lu, M., Kennedy, G., Chun, J., FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. U. S. A. 108:2 (2011), 751–756.
41. [41] Bigaud, M., Guerini, D., Billich, A., Bassilana, F., Brinkmann, V., Second generation S1P pathway modulators: research strategies and clinical developments. Biochim. Biophys. Acta 1841:5 (2014), 745–758.
42. [42] Roberts, E., Guerrero, M., Urbano, M., Rosen, H., Sphingosine 1-phosphate receptor agonists: a patent review (2010 − 2012). Expert Opin. Ther. Pat. 23:7 (2013), 817–841.
43. [43] Kim, G.S., Yang, L., Zhang, G., Zhao, H., Selim, M., McCullough, L.D., Kluk, M.J., Sanchez, T., Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nat. Commun., 6, 2015, 7893.
44. [44] Oskeritzian, C.A., Hait, N.C., Wedman, P., Chumanevich, A., Kolawole, E.M., Price, M.M., Falanga, Y.T., Harikumar, K.B., Ryan, J.J., Milstien, S., Sabbadini, R., Spiegel, S., The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses. J. Allergy Clin. Immunol. 135:4 (2015), 1008–1018, e1.
45. [45] Yamamoto, S., Yako, Y., Fujioka, Y., Kajita, M., Kameyama, T., Kon, S., Ishikawa, S., Ohba, Y., Ohno, Y., Kihara, A., Fujita, Y., A role of the sphingosine-1-phosphate (S1P)-S1P receptor 2 pathway in epithelial defense against cancer (EDAC). Mol. Biol. Cell 27:3 (2016), 491–499.
46. [46] Pyne, N.J., Pyne, S., Selectivity and specificity of sphingosine 1-phosphate receptor ligands: “off-targets” or complex pharmacology?. Front. Pharmacol., 2, 2011, 26.
47. [47] Long, J.S., Fujiwara, Y., Edwards, J., Tannahill, C.L., Tigyi, G., Pyne, S., Pyne, N.J., Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 285:46 (2010), 35957–35966.
48. [48] Salomone, S., Waeber, C., Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects. Front. Pharmacol., 2, 2011, 9.
49. [49] Herr, D.R., Reolo, M.J., Peh, Y.X., Wang, W., Lee, C.W., Rivera, R., Paterson, I.C., Chun, J., Sphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy. Sci. Rep., 6, 2016, 24541.
50. [50] Satsu, H., Schaeffer, M.T., Guerrero, M., Saldana, A., Eberhart, C., Hodder, P., Cayanan, C., Schurer, S., Bhhatarai, B., Roberts, E., Rosen, H., Brown, S.J., A sphingosine 1-phosphate receptor 2 selective allosteric agonist. Bioorg. Med. Chem. 21:17 (2013), 5373–5382.
51. [51] Patmanathan, S.N., Johnson, S.P., Lai, S.L., Panja Bernam, S., Lopes, V., Wei, W., Ibrahim, M.H., Torta, F., Narayanaswamy, P., Wenk, M.R., Herr, D.R., Murray, P.G., Yap, L.F., Paterson, I.C., Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2. Sci. Rep., 6, 2016, 25650.
52. [52] Park, S.W., Kim, M., Brown, K.M., D'Agati, V.D., Lee, H.T., Inhibition of sphingosine 1-phosphate receptor 2 protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 23:2 (2012), 266–280.
53. [53] Murakami, A., Takasugi, H., Ohnuma, S., Koide, Y., Sakurai, A., Takeda, S., Hasegawa, T., Sasamori, J., Konno, T., Hayashi, K., Watanabe, Y., Mori, K., Sato, Y., Takahashi, A., Mochizuki, N., Takakura, N., Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol. Pharmacol. 77:4 (2010), 704–713.
54. [54] Jo, E., Bhhatarai, B., Repetto, E., Guerrero, M., Riley, S., Brown, S.J., Kohno, Y., Roberts, E., Schurer, S.C., Rosen, H., Novel selective allosteric and bitopic ligands for the S1P(3) receptor. ACS Chem. Biol. 7:12 (2012), 1975–1983.
55. [55] Urbano, M., Guerrero, M., Velaparthi, S., Crisp, M., Chase, P., Hodder, P., Schaeffer, M.T., Brown, S., Rosen, H., Roberts, E., Discovery, synthesis and SAR analysis of novel selective small molecule S1P4-R agonists based on a (2Z,5Z)-5-((pyrrol-3-yl)methylene)-3-alkyl-2-(alkylimino)thiazolidin-4-one chemotype. Bioorg. Med. Chem. Lett. 21:22 (2011), 6739–6745.
56. [56] Hur, W., Rosen, H., Gray, N.S., A benzo[b]thiophene-based selective type 4 S1P receptor agonist. Bioorg. Med. Chem. Lett. 27:1 (2017), 1–5.
57. [57] Li, M.H., Sanchez, T., Yamase, H., Hla, T., Oo, M.L., Pappalardo, A., Lynch, K.R., Lin, C.Y., Ferrer, F., S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett. 276:2 (2009), 171–179.
58. [58] Fisher, K.E., Pop, A., Koh, W., Anthis, N.J., Saunders, W.B., Davis, G.E., Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling. Mol. Cancer, 5, 2006, 69.
59. [59] Young, N., Pearl, D.K., Van Brocklyn, J.R., Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol. Cancer Res. 7:1 (2009), 23–32.
60. [60] Choi, J.W., Lee, C.W., Chun, J., Biological roles of lysophospholipid receptors revealed by genetic null mice: an update. Biochim. Biophys. Acta 1781:9 (2008), 531–539.
61. [61] Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.X., Hobson, J.P., Rosenfeldt, H.M., Nava, V.E., Chae, S.S., Lee, M.J., Liu, C.H., Hla, T., Spiegel, S., Proia, R.L., Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106:8 (2000), 951–961.
62. [62] Chae, S.S., Paik, J.H., Furneaux, H., Hla, T., Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. 114:8 (2004), 1082–1089.
63. [63] Liang, J., Nagahashi, M., Kim, E.Y., Harikumar, K.B., Yamada, A., Huang, W.C., Hait, N.C., Allegood, J.C., Price, M.M., Avni, D., Takabe, K., Kordula, T., Milstien, S., Spiegel, S., Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23:1 (2013), 107–120.
64. [64] Cattoretti, G., Mandelbaum, J., Lee, N., Chaves, A.H., Mahler, A.M., Chadburn, A., Dalla-Favera, R., Pasqualucci, L., MacLennan, A.J., Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 69:22 (2009), 8686–8692.
65. [65] Yamamura, S., Hakomori, S., Wada, A., Igarashi, Y., Sphingosine-1-phosphate inhibits haptotactic motility by overproduction of focal adhesion sites in B16 melanoma cells through EDG-induced activation of Rho. Ann. N. Y. Acad. Sci. 905 (2000), 301–307.
66. [66] Arikawa, K., Takuwa, N., Yamaguchi, H., Sugimoto, N., Kitayama, J., Nagawa, H., Takehara, K., Takuwa, Y., Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J. Biol. Chem. 278:35 (2003), 32841–32851.
67. [67] Yamaguchi, H., Kitayama, J., Takuwa, N., Arikawa, K., Inoki, I., Takehara, K., Nagawa, H., Takuwa, Y., Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem. J. 374:Pt 3 (2003), 715–722.
68. [68] Lepley, D., Paik, J.H., Hla, T., Ferrer, F., The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res. 65:9 (2005), 3788–3795.
69. [69] Li, M.H., Sanchez, T., Pappalardo, A., Lynch, K.R., Hla, T., Ferrer, F., Induction of antiproliferative connective tissue growth factor expression in Wilms’ tumor cells by sphingosine-1-phosphate receptor 2. Mol. Cancer Res. 6:10 (2008), 1649–1656.
70. [70] Du, W., Takuwa, N., Yoshioka, K., Okamoto, Y., Gonda, K., Sugihara, K., Fukamizu, A., Asano, M., Takuwa, Y., S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res. 70:2 (2010), 772–781.
71. [71] An, S., Zheng, Y., Bleu, T., Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5. J. Biol. Chem. 275:1 (2000), 288–296.
72. [72] Young, N., Van Brocklyn, J.R., Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp. Cell Res. 313:8 (2007), 1615–1627.
73. [73] Li, M.H., Sanchez, T., Milne, G.L., Morrow, J.D., Hla, T., Ferrer, F., S1P/S1P2 signaling induces cyclooxygenase-2 expression in Wilms tumor. J. Urol. 181:3 (2009), 1347–1352.
74. [74] Ponnusamy, S., Selvam, S.P., Mehrotra, S., Kawamori, T., Snider, A.J., Obeid, L.M., Shao, Y., Sabbadini, R., Ogretmen, B., Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol. Med. 4:8 (2012), 761–775.
75. [75] Salas, A., Ponnusamy, S., Senkal, C.E., Meyers-Needham, M., Selvam, S.P., Saddoughi, S.A., Apohan, E., Sentelle, R.D., Smith, C., Gault, C.R., Obeid, L.M., El-Shewy, H.M., Oaks, J., Santhanam, R., Marcucci, G., Baran, Y., Mahajan, S., Fernandes, D., Stuart, R., Perrotti, D., Ogretmen, B., Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 117:22 (2011), 5941–5952.
76. [76] Gan, C.P., Patel, V., Mikelis, C.M., Zain, R.B., Molinolo, A.A., Abraham, M.T., Teo, S.H., Abdul Rahman, Z.A., Gutkind, J.S., Cheong, S.C., Heterotrimeric G-protein alpha-12 (Galpha12) subunit promotes oral cancer metastasis. Oncotarget 5:20 (2014), 9626–9640.
77. [77] Goetzl, E.J., Dolezalova, H., Kong, Y., Zeng, L., Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Res. 59:18 (1999), 4732–4737.
78. [78] Watson, C., Long, J.S., Orange, C., Tannahill, C.L., Mallon, E., McGlynn, L.M., Pyne, S., Pyne, N.J., Edwards, J., High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am. J. Pathol. 177:5 (2010), 2205–2215.
79. [79] Magrassi, L., Marziliano, N., Inzani, F., Cassini, P., Chiaranda, I., Skrap, M., Pizzolito, S., Arienta, C., Arbustini, E., EDG3 and SHC3 on chromosome 9q22 are co-amplified in human ependymomas. Cancer Lett. 290:1 (2010), 36–42.
80. [80] Sugimoto, N., Takuwa, N., Okamoto, H., Sakurada, S., Takuwa, Y., Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol. Cell. Biol. 23:5 (2003), 1534–1545.
81. [81] Yamashita, H., Kitayama, J., Shida, D., Yamaguchi, H., Mori, K., Osada, M., Aoki, S., Yatomi, Y., Takuwa, Y., Nagawa, H., Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J. Surg. Res. 130:1 (2006), 80–87.
82. [82] Kim, E.S., Kim, J.S., Kim, S.G., Hwang, S., Lee, C.H., Moon, A., Sphingosine 1-phosphate regulates matrix metalloproteinase-9 expression and breast cell invasion through S1P3-Galphaq coupling. J. Cell Sci. 124:Pt 13 (2011), 2220–2230.
83. [83] Filipenko, I., Schwalm, S., Reali, L., Pfeilschifter, J., Fabbro, D., Huwiler, A., Zangemeister-Wittke, U., Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation. Biochim. Biophys. Acta 1861:11 (2016), 1840–1851.
84. [84] Lee, H.M., Lo, K.W., Wei, W., Tsao, S.W., Chung, G.T., Ibrahim, M.H., Dawson, C.W., Murray, P.G., Paterson, I.C., Yap, L.F., Oncogenic S1P signalling in EBV-associated nasopharyngeal carcinoma activates AKT and promotes cell migration through S1P receptor 3. J. Pathol., Feb 27 2017, 10.1002/path.4879 (E-pub ahead of print).
85. [85] Lee, M.J., Thangada, S., Claffey, K.P., Ancellin, N., Liu, C.H., Kluk, M., Volpi, M., Sha'afi, R.I., Hla, T., Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99:3 (1999), 301–312.
86. [86] Kimura, T., Watanabe, T., Sato, K., Kon, J., Tomura, H., Tamama, K., Kuwabara, A., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., Okajima, F., Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem. J. 348:Pt 1 (2000), 71–76.
87. [87] Paik, J.H., Chae, S., Lee, M.J., Thangada, S., Hla, T., Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J. Biol. Chem. 276:15 (2001), 11830–11837.
88. [88] Wang, F., Van Brocklyn, J.R., Hobson, J.P., Movafagh, S., Zukowska-Grojec, Z., Milstien, S., Spiegel, S., Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis. J. Biol. Chem. 274:50 (1999), 35343–35350.
89. [89] Hirata, N., Yamada, S., Shoda, T., Kurihara, M., Sekino, Y., Kanda, Y., Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat. Commun., 5, 2014, 4806.
90. [90] Ohotski, J., Long, J.S., Orange, C., Elsberger, B., Mallon, E., Doughty, J., Pyne, S., Pyne, N.J., Edwards, J., Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 106:8 (2012), 1453–1459.
91. [91] Hu, W.M., Li, L., Jing, B.Q., Zhao, Y.S., Wang, C.L., Feng, L., Xie, Y.E., Effect of S1P5 on proliferation and migration of human esophageal cancer cells. World J. Gastroenterol. 16:15 (2010), 1859–1866.
92. [92] Chang, C.L., Ho, M.C., Lee, P.H., Hsu, C.Y., Huang, W.P., Lee, H., S1P(5) is required for sphingosine 1-phosphate-induced autophagy in human prostate cancer PC-3 cells. Am. J. Phys. Cell Physiol. 297:2 (2009), C451–C458.
93. [93] Huang, Y.L., Chang, C.L., Tang, C.H., Lin, Y.C., Ju, T.K., Huang, W.P., Lee, H., Extrinsic sphingosine 1-phosphate activates S1P5 and induces autophagy through generating endoplasmic reticulum stress in human prostate cancer PC-3 cells. Cell. Signal. 26:3 (2014), 611–618.
94. [94] Balthasar, S., Samulin, J., Ahlgren, H., Bergelin, N., Lundqvist, M., Toescu, E.C., Eggo, M.C., Tornquist, K., Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells. Biochem. J. 398:3 (2006), 547–556.
95. [95] Takuwa, N., Du, W., Kaneko, E., Okamoto, Y., Yoshioka, K., Takuwa, Y., Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. Am. J. Cancer Res. 1:4 (2011), 460–481.
96. [96] Yang, L., Yue, S., Yang, L., Liu, X., Han, Z., Zhang, Y., Li, L., Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J. Hepatol. 59:1 (2013), 114–123.
97. [97] Wang, F., Van Brocklyn, J.R., Edsall, L., Nava, V.E., Spiegel, S., Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. Cancer Res. 59:24 (1999), 6185–6191.
98. [98] Quint, K., Stiel, N., Neureiter, D., Schlicker, H.U., Nimsky, C., Ocker, M., Strik, H., Kolodziej, M.A., The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas. Tumour Biol. 35:9 (2014), 8979–8989.
99. [99] Li, C., Li, J.N., Kays, J., Guerrero, M., Nicol, G.D., Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3. J. Neuroinflammation, 12, 2015, 70.
100. [100] Kong, Y., Wang, H., Lin, T., Wang, S., Sphingosine-1-phosphate/S1P receptors signaling modulates cell migration in human bone marrow-derived mesenchymal stem cells. Mediat. Inflamm., 2014, 2014, 565369.
101. [101] Yang, L., Han, Z., Tian, L., Mai, P., Zhang, Y., Wang, L., Li, L., Sphingosine 1-phosphate receptor 2 and 3 mediate bone marrow-derived monocyte/macrophage motility in cholestatic liver injury in mice. Sci. Rep., 5, 2015, 13423.
102. [102] Bhosle, V.K., Rivera, J.C., Chemtob, S., New insights into mechanisms of nuclear translocation of G-protein coupled receptors. Small GTPases, 0, 2017.
103. [103] Gobeil, F. Jr., Bernier, S.G., Vazquez-Tello, A., Brault, S., Beauchamp, M.H., Quiniou, C., Marrache, A.M., Checchin, D., Sennlaub, F., Hou, X., Nader, M., Bkaily, G., Ribeiro-da-Silva, A., Goetzl, E.J., Chemtob, S., Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J. Biol. Chem. 278:40 (2003), 38875–38883.
104. [104] Moughal, N.A., Waters, C., Sambi, B., Pyne, S., Pyne, N.J., Nerve growth factor signaling involves interaction between the Trk A receptor and lysophosphatidate receptor 1 systems: nuclear translocation of the lysophosphatidate receptor 1 and Trk 4 receptors in pheochromocytoma 12 cells. Cell. Signal. 16:1 (2004), 127–136.
105. [105] Waters, C.M., Saatian, B., Moughal, N.A., Zhao, Y., Tigyi, G., Natarajan, V., Pyne, S., Pyne, N.J., Integrin signalling regulates the nuclear localization and function of the lysophosphatidic acid receptor-1 (LPA1) in mammalian cells. Biochem. J. 398:1 (2006), 55–62.
106. [106] Wang, Y.H., Tian, X., Liu, O.S., Fang, X.D., Quan, H.Z., Xie, S., Gao, S., Tang, Z.G., Gene profiling analysis for patients with oral verrucous carcinoma and oral squamous cell carcinoma. Int. J. Clin. Exp. Med. 7:7 (2014), 1845–1852.
107. [107] Gillies, L., Lee, S.C., Long, J.S., Ktistakis, N., Pyne, N.J., Pyne, S., The sphingosine 1-phosphate receptor 5 and sphingosine kinases 1 and 2 are localised in centrosomes: possible role in regulating cell division. Cell. Signal. 21:5 (2009), 675–684.
108. [108] Ohotski, J., Rosen, H., Bittman, R., Pyne, S., Pyne, N.J., Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: the role of sphingosine 1-phosphate receptor-4. Cell. Signal. 26:5 (2014), 1040–1047.
109. [109] Adada, M.M., Canals, D., Jeong, N., Kelkar, A.D., Hernandez-Corbacho, M., Pulkoski-Gross, M.J., Donaldson, J.C., Hannun, Y.A., Obeid, L.M., Intracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrin-radixin-moesini phosphorylation and cancer cell invasion. FASEB J. 29:11 (2015), 4654–4669.
110. [110] Ferre, S., Casado, V., Devi, L.A., Filizola, M., Jockers, R., Lohse, M.J., Milligan, G., Pin, J.P., Guitart, X., G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol. Rev. 66:2 (2014), 413–434.
111. [111] Prinster, S.C., Hague, C., Hall, R.A., Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol. Rev. 57:3 (2005), 289–298.
112. [112] Van Brocklyn, J.R., Behbahani, B., Lee, N.H., Homodimerization and heterodimerization of S1P/EDG sphingosine-1-phosphate receptors. Biochim. Biophys. Acta 1582:1–3 (2002), 89–93.
113. [113] Zaslavsky, A., Singh, L.S., Tan, H., Ding, H., Liang, Z., Xu, Y., Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4. Biochim. Biophys. Acta 1761:10 (2006), 1200–1212.
114. [114] Akekawatchai, C., Holland, J.D., Kochetkova, M., Wallace, J.C., McColl, S.R., Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J. Biol. Chem. 280:48 (2005), 39701–39708.
115. [115] Delcourt, N., Bockaert, J., Marin, P., GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol. Sci. 28:12 (2007), 602–607.
116. [116] Borroto-Escuela, D.O., Romero-Fernandez, W., Mudo, G., Perez-Alea, M., Ciruela, F., Tarakanov, A.O., Narvaez, M., Di Liberto, V., Agnati, L.F., Belluardo, N., Fuxe, K., Fibroblast growth factor receptor 1–5-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity. Biol. Psychiatry 71:1 (2012), 84–91.
117. [117] Flajolet, M., Wang, Z., Futter, M., Shen, W., Nuangchamnong, N., Bendor, J., Wallach, I., Nairn, A.C., Surmeier, D.J., Greengard, P., FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 11:12 (2008), 1402–1409.
118. [118] Alderton, F., Rakhit, S., Kong, K.C., Palmer, T., Sambi, B., Pyne, S., Pyne, N.J., Tethering of the platelet-derived growth factor beta receptor to G-protein-coupled receptors. A novel platform for integrative signaling by these receptor classes in mammalian cells. J. Biol. Chem. 276:30 (2001), 28578–28585.
119. [119] Long, J.S., Natarajan, V., Tigyi, G., Pyne, S., Pyne, N.J., The functional PDGFbeta receptor-S1P1 receptor signaling complex is involved in regulating migration of mouse embryonic fibroblasts in response to platelet derived growth factor. Prostaglandins Other Lipid Mediat. 80:1–2 (2006), 74–80.
120. [120] Waters, C., Sambi, B., Kong, K.C., Thompson, D., Pitson, S.M., Pyne, S., Pyne, N.J., Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGF beta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells. J. Biol. Chem. 278:8 (2003), 6282–6290.
121. [121] Waters, C.M., Long, J., Gorshkova, I., Fujiwara, Y., Connell, M., Belmonte, K.E., Tigyi, G., Natarajan, V., Pyne, S., Pyne, N.J., Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J. 20:3 (2006), 509–511.
122. [122] Bergelin, N., Lof, C., Balthasar, S., Kalhori, V., Tornquist, K., S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology 151:7 (2010), 2994–3005.
123. [123] Hobson, J.P., Rosenfeldt, H.M., Barak, L.S., Olivera, A., Poulton, S., Caron, M.G., Milstien, S., Spiegel, S., Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science (New York, N.Y.) 291:5509 (2001), 1800–1803.
124. [124] Igarashi, J., Erwin, P.A., Dantas, A.P., Chen, H., Michel, T., VEGF induces S1P1 receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors. Proc. Natl. Acad. Sci. U. S. A. 100:19 (2003), 10664–10669.
125. [125] Shida, D., Fang, X., Kordula, T., Takabe, K., Lepine, S., Alvarez, S.E., Milstien, S., Spiegel, S., Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 68:16 (2008), 6569–6577.
126. [126] Cencetti, F., Bruno, G., Blescia, S., Bernacchioni, C., Bruni, P., Donati, C., Lysophosphatidic acid stimulates cell migration of satellite cells. A role for the sphingosine kinase/sphingosine 1-phosphate axis. FEBS J. 281:19 (2014), 4467–4478.
127. [127] French, K.J., Zhuang, Y., Maines, L.W., Gao, P., Wang, W., Beljanski, V., Upson, J.J., Green, C.L., Keller, S.N., Smith, C.D., Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther. 333:1 (2010), 129–139.
128. [128] Schrecengost, R.S., Keller, S.N., Schiewer, M.J., Knudsen, K.E., Smith, C.D., Downregulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression. Mol. Cancer Res. 13:12 (2015), 1591–1601.
129. [129] Xun, C., Chen, M.B., Qi, L., Tie-Ning, Z., Peng, X., Ning, L., Zhi-Xiao, C., Li-Wei, W., Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J. Exp. Clin. Cancer Res., 34, 2015, 94.
130. [130] Venant, H., Rahmaniyan, M., Jones, E.E., Lu, P., Lilly, M.B., Garrett-Mayer, E., Drake, R.R., Kraveka, J.M., Smith, C.D., Voelkel-Johnson, C., The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Mol. Cancer Ther. 14:12 (2015), 2744–2752.
131. [131] McNaughton, M., Pitman, M., Pitson, S.M., Pyne, N.J., Pyne, S., Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget 7:13 (2016), 16663–16675.
132. [132] O'Brien, N., Jones, S.T., Williams, D.G., Cunningham, H.B., Moreno, K., Visentin, B., Gentile, A., Vekich, J., Shestowsky, W., Hiraiwa, M., Matteo, R., Cavalli, A., Grotjahn, D., Grant, M., Hansen, G., Campbell, M.A., Sabbadini, R., Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J. Lipid Res. 50:11 (2009), 2245–2257.
133. [133] Patmanathan, S.N., Yap, L.F., Murray, P.G., Paterson, I.C., The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod. J. Cell. Mol. Med., 2015.
134. [134] Joyal, J.S., Bhosle, V.K., Chemtob, S., Subcellular G-protein coupled receptor signaling hints at greater therapeutic selectivity. Expert Opin. Ther. Targets 19:6 (2015), 717–721.